Roger Song
Stock Analyst at Jefferies
(0.69)
# 3,702
Out of 4,711 analysts
41
Total ratings
23.53%
Success rate
-22.41%
Average return
Main Sectors:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIOA BioAge Labs | Downgrades: Hold | $42 → $7 | $6.14 | +14.01% | 2 | Dec 9, 2024 | |
| REPL Replimune Group | Maintains: Buy | $16 → $19 | $12.49 | +52.12% | 1 | Dec 4, 2024 | |
| KURA Kura Oncology | Maintains: Buy | $32 → $28 | $9.01 | +210.77% | 2 | Nov 21, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Buy | $2 → $7 | $2.72 | +157.35% | 1 | Nov 19, 2024 | |
| IRON Disc Medicine | Initiates: Buy | $89 | $64.50 | +37.98% | 1 | Oct 23, 2024 | |
| NVAX Novavax | Maintains: Buy | $31 → $25 | $8.70 | +187.36% | 2 | Oct 16, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Buy | $41 | $19.83 | +106.76% | 1 | Oct 11, 2024 | |
| ZBIO Zenas BioPharma | Initiates: Buy | $35 | $10.01 | +249.65% | 1 | Oct 8, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Initiates: Buy | $40 | $20.59 | +94.27% | 1 | Sep 13, 2024 | |
| ATYR aTyr Pharma | Initiates: Buy | $9 | $3.35 | +168.66% | 1 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $86.53 | +49.08% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2.5 → $8 | $1.09 | +633.94% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $84.22 | +15.17% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $72 | $20.65 | +248.67% | 2 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $42.25 | +160.36% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $0.5 → $1 | $0.93 | +7.72% | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $61 → $55 | $6.90 | +697.10% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $8.25 | +324.24% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.30 | +592.31% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $675 | $3.39 | +19,811.50% | 1 | Jan 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $4.99 | +60.32% | 2 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3 → $4 | $0.23 | +1,610.13% | 2 | Nov 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $315 | $0.16 | +196,775.00% | 1 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.88 | +1,017.02% | 1 | Sep 2, 2020 |
BioAge Labs
Dec 9, 2024
Downgrades: Hold
Price Target: $42 → $7
Current: $6.14
Upside: +14.01%
Replimune Group
Dec 4, 2024
Maintains: Buy
Price Target: $16 → $19
Current: $12.49
Upside: +52.12%
Kura Oncology
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $9.01
Upside: +210.77%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $2.72
Upside: +157.35%
Disc Medicine
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $64.50
Upside: +37.98%
Novavax
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $8.70
Upside: +187.36%
Nurix Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $19.83
Upside: +106.76%
Zenas BioPharma
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $10.01
Upside: +249.65%
Kiniksa Pharmaceuticals International,
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $20.59
Upside: +94.27%
aTyr Pharma
Sep 5, 2024
Initiates: Buy
Price Target: $9
Current: $3.35
Upside: +168.66%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $86.53
Upside: +49.08%
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $1.09
Upside: +633.94%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $84.22
Upside: +15.17%
Mar 20, 2024
Maintains: Buy
Price Target: $41 → $72
Current: $20.65
Upside: +248.67%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $42.25
Upside: +160.36%
Mar 6, 2024
Maintains: Hold
Price Target: $0.5 → $1
Current: $0.93
Upside: +7.72%
Nov 9, 2022
Assumes: Buy
Price Target: $61 → $55
Current: $6.90
Upside: +697.10%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $8.25
Upside: +324.24%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $1.30
Upside: +592.31%
Jan 11, 2022
Initiates: Buy
Price Target: $675
Current: $3.39
Upside: +19,811.50%
Dec 1, 2021
Initiates: Buy
Price Target: $8
Current: $4.99
Upside: +60.32%
Nov 12, 2021
Upgrades: Buy
Price Target: $3 → $4
Current: $0.23
Upside: +1,610.13%
Sep 8, 2020
Initiates: Buy
Price Target: $315
Current: $0.16
Upside: +196,775.00%
Sep 2, 2020
Initiates: Buy
Price Target: $21
Current: $1.88
Upside: +1,017.02%